2008年至2014年在美国医疗中心，头孢洛林及对照药物对皮肤和皮肤结构感染患者中引起菌血症的细菌的抗菌活性。
Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.
作者信息
Sader Helio S, Flamm Robert K, Mendes Rodrigo E, Farrell David J, Jones Ronald N
机构信息
JMI Laboratories, North Liberty, Iowa, USA
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2558-63. doi: 10.1128/AAC.02794-15. Print 2016 Apr.
Abstract
We evaluated the antimicrobial susceptibility of 1,454 organisms consecutively collected from patients with bacteremia associated with skin and skin structure infections. The most common organisms obtained wereStaphylococcus aureus(670 organisms [46.1%]),Escherichia coli(200 organisms [13.8%]), β-hemolytic streptococci (βHS) (138 organisms [9.5%]), andKlebsiella pneumoniae(109 organisms [7.5%]). The susceptibility rates for ceftaroline were 97.9% forS. aureus(95.9% among methicillin-resistantS. aureus[MRSA]), 100.0% for βHS, 86.5% forE. coli, and 89.0% forK. pneumoniae Ceftaroline and tigecycline provided the best overall coverage.
摘要
我们评估了从患有与皮肤及皮肤结构感染相关菌血症的患者中连续收集的1454株微生物的抗菌药敏性。分离出的最常见微生物为金黄色葡萄球菌（670株 [46.1%]）、大肠埃希菌（200株 [13.8%]）、β溶血性链球菌（βHS）（138株 [9.5%]）和肺炎克雷伯菌（109株 [7.5%]）。头孢洛林对金黄色葡萄球菌的药敏率为97.9%（耐甲氧西林金黄色葡萄球菌 [MRSA] 中为95.9%），对βHS为100.0%，对大肠埃希菌为86.5%，对肺炎克雷伯菌为89.0%。头孢洛林和替加环素提供了最佳的总体覆盖范围。
相似文献
1
Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2558-63. doi: 10.1128/AAC.02794-15. Print 2016 Apr.
2
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Diagn Microbiol Infect Dis. 2013 May;76(1):61-8. doi: 10.1016/j.diagmicrobio.2013.01.005. Epub 2013 Mar 25.
3
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
Pediatr Infect Dis J. 2017 May;36(5):486-491. doi: 10.1097/INF.0000000000001477.
4
Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).
Diagn Microbiol Infect Dis. 2014 Apr;78(4):449-56. doi: 10.1016/j.diagmicrobio.2014.01.003. Epub 2014 Jan 14.
5
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Diagn Microbiol Infect Dis. 2014 Apr;78(4):422-8. doi: 10.1016/j.diagmicrobio.2013.08.027. Epub 2014 Jan 18.
6
Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014).
Diagn Microbiol Infect Dis. 2016 Sep;86(1):76-9. doi: 10.1016/j.diagmicrobio.2016.06.017. Epub 2016 Jun 23.
7
Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).
Int J Antimicrob Agents. 2013 Apr;41(4):337-42. doi: 10.1016/j.ijantimicag.2012.12.013. Epub 2013 Mar 5.
8
Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Pediatr Infect Dis J. 2014 Aug;33(8):837-42. doi: 10.1097/INF.0000000000000307.
9
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.
Diagn Microbiol Infect Dis. 2015 May;82(1):78-84. doi: 10.1016/j.diagmicrobio.2015.01.015. Epub 2015 Feb 10.
10
A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology.
Int J Antimicrob Agents. 2015 Apr;45(4):347-50. doi: 10.1016/j.ijantimicag.2014.12.014. Epub 2015 Jan 15.
引用本文的文献
1
PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens.
Antimicrob Agents Chemother. 2023 May 17;67(5):e0151922. doi: 10.1128/aac.01519-22. Epub 2023 Apr 26.
2
and Properties of CUO246, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0092122. doi: 10.1128/aac.00921-22. Epub 2022 Nov 30.
3
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
BMC Microbiol. 2022 Oct 1;22(1):234. doi: 10.1186/s12866-022-02644-5.
4
Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016).
Antimicrob Resist Infect Control. 2020 Oct 27;9(1):166. doi: 10.1186/s13756-020-00829-z.
5
The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.
Antimicrob Resist Infect Control. 2020 Apr 22;9(1):56. doi: 10.1186/s13756-020-00714-9.
6
Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977).
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00120-17. Print 2017 Jun.
本文引用的文献
1
Implementation of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in Routine Clinical Laboratories Improves Identification of Coagulase-Negative Staphylococci and Reveals the Pathogenic Role of Staphylococcus lugdunensis.
J Clin Microbiol. 2015 Jul;53(7):2030-6. doi: 10.1128/JCM.00177-15. Epub 2015 Apr 15.
2
Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.
N Engl J Med. 2015 Mar 19;372(12):1093-103. doi: 10.1056/NEJMoa1403789.
3
Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.
Antimicrob Agents Chemother. 2015 Apr;59(4):2458-61. doi: 10.1128/AAC.04614-14. Epub 2015 Feb 2.
4
Ceftaroline Fosamil for the Treatment of Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia.
Infect Dis Clin Pract (Baltim Md). 2015 Jan;23(1):39-43. doi: 10.1097/IPC.0000000000000191.
5
Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study.
J Antimicrob Chemother. 2014 Jul;69(7):2010-3. doi: 10.1093/jac/dku085. Epub 2014 Mar 28.
6
Microbial etiology and antimicrobial resistance in healthcare-associated versus community-acquired and hospital-acquired bloodstream infection in a tertiary care hospital.
Diagn Microbiol Infect Dis. 2013 Dec;77(4):341-5. doi: 10.1016/j.diagmicrobio.2013.08.009. Epub 2013 Sep 26.
7
National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011.
JAMA Intern Med. 2013 Nov 25;173(21):1970-8. doi: 10.1001/jamainternmed.2013.10423.
8
Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Drugs. 2013 Jul;73(10):1067-94. doi: 10.1007/s40265-013-0075-6.
9
Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.
Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14. doi: 10.1086/668770. Epub 2012 Nov 27.
10
Trends in sources of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia: data from the national mandatory surveillance of MRSA bacteraemia in England, 2006-2009.
J Hosp Infect. 2011 Nov;79(3):211-7. doi: 10.1016/j.jhin.2011.05.013. Epub 2011 Jul 20.
Zotero 插件